How do I arrange CAR-T therapy in China as an international patient?

Typical steps: share your diagnosis and medical records for remote review by the Chinese centre; confirm eligibility, the specific product, and a written cost estimate; arrange a medical visa and travel; complete on-site evaluation, cell collection, manufacturing, and reinfusion; then plan monitoring and handover to your home oncologist. Most patients should budget several weeks in-country. An independent, fee-only coordinator can manage records, scheduling, interpreters, and verification without steering you toward any particular facility.

What questions should I ask before choosing an overseas cancer treatment centre?

Ask whether the therapy is fully approved or offered under a clinical trial; how many patients with your specific cancer the centre has treated and their outcomes; what the all-in written cost covers; how complications like cytokine release syndrome are managed; what English-language support exists for consent and daily care; and how follow-up will be coordinated with your oncologist at home.

Insights · Cross-Border Care

Why Cancer Patients Are Flying to China for Treatment

Q: How much does CAR-T therapy cost in China compared to the US?

Base CAR-T treatment in China is widely reported at roughly US$30,000–$140,000 depending on the product and hospital, compared with roughly US$275,000–$475,000 in the United States before hospital and supportive-care costs. Total costs including hospitalisation are typically several times lower in China. Prices vary by product, hospital, and case complexity, so always obtain a written quote.

Q: Why is CAR-T treatment faster in China?

Chinese centres often manufacture a patient's engineered cells locally in days — cases of around eight days from collection to reinfusion have been reported — versus the weeks or months common in Western systems. For fast-progressing blood cancers, that speed can determine whether a patient is still well enough to receive the therapy.

Q: Is it safe for foreigners to get cancer treatment in China?

Leading Chinese academic hospitals run some of the world's largest CAR-T programmes, and China had eight regulator-approved CAR-T products as of late 2025 — slightly more than the US. But quality varies between institutions, some therapies are offered under trial frameworks rather than full approval, and language, consent documentation, and follow-up care at home all need careful planning. Independent verification of the specific hospital, product, and protocol is essential.

By the Lengdeh Team · Published 2 August 2026 · Last updated 2 August 2026 · 8 min read

In short: A growing number of international cancer patients are travelling to China for advanced therapies — above all CAR-T cell therapy — because treatment there can cost a fraction of the US price (roughly US$30,000–$140,000 versus US$275,000–$475,000 for the therapy alone), and because Chinese centres can manufacture a patient's engineered cells in days rather than weeks or months. As of late 2025, China had more regulator-approved CAR-T products than the United States. The opportunity is real, but so is the need for careful, independent verification.

The BBC World Service recently dedicated an episode of its Asia Specific podcast to this phenomenon — why patients from Australia, Europe, North America and Southeast Asia are boarding flights to Shanghai and Beijing for cancer treatment they cannot access, or cannot afford, at home. It is worth twenty minutes of your time:

"Why cancer patients are flying to China for treatment" — Asia Specific podcast, BBC World Service. Watch on YouTube.

What is CAR-T cell therapy?

CAR-T (chimeric antigen receptor T-cell) therapy is a personalised cancer treatment in which a patient's own immune cells are collected, genetically engineered in a laboratory to recognise and attack their cancer, then reinfused into the body. It has produced remarkable results in certain blood cancers — leukaemias, lymphomas and multiple myeloma — including in patients who had exhausted other options. It is also one of the most expensive treatments in modern medicine, which is exactly why geography has started to matter so much.

How much does CAR-T therapy cost in China vs the West?

The cost gap is the single biggest driver of this trend. Published figures vary by product and hospital, but the pattern is consistent:

	China	United States
CAR-T therapy (base)	≈ US$30,000–$140,000	≈ US$275,000–$475,000
Typical all-in cost (with hospitalisation & supportive care)	≈ US$45,000–$180,000	US$400,000–$550,000+
Cell manufacturing time	Days (cases of ~8 days reported)	Commonly several weeks to 2–3 months
Approved CAR-T products (as of late Nov 2025)	8 (NMPA)	7 (FDA)

Ranges compiled from BBC World Service reporting, Yicai Global (Nov 2025) and industry coverage (2025–2026). Actual quotes depend on the product, hospital, and case complexity — always obtain a written, itemised estimate.

One case featured in the BBC's reporting: an Australian doctor with cancer paid roughly AUD 110,000 (about US$70,000) for CAR-T treatment in Shanghai, against an estimated AUD 1 million pathway at home — and her engineered cells were ready for reinfusion within about eight days of collection.

Why is China suddenly a destination for advanced cancer care?

Four forces converged over the past few years:

Trial volume. China now runs more CAR-T clinical trials than the US and Europe combined — over 500 active trials as of 2025 — giving major centres unusually deep hands-on experience. A University of Hong Kong haematologist quoted by Yicai Global put it plainly: in the last one to two years, more CAR-T procedures have probably been performed in China than anywhere else in the world.
Local manufacturing. Domestic production compresses both cost and the vein-to-vein timeline — critical for patients whose disease is progressing week by week.
A dual-track regulatory system. Top-tier hospitals can offer cutting-edge therapies through investigator-initiated trials, sometimes years before equivalent Western approval. In early 2026, China approved the world's first CAR-T therapy targeting solid tumours.
Deliberate openness to international patients. Dedicated international centres have emerged: one Shanghai international CAR-T centre reported over 100 overseas inquiries and more than 20 foreign patients treated — from a dozen countries including Singapore, the UK, Germany, France, Canada and New Zealand — within months of opening in May 2025.

The risks nobody should gloss over

Enthusiasm is not a substitute for diligence. Quality varies significantly between institutions. Some therapies are offered under trial frameworks rather than full regulatory approval, which changes the consent, insurance, and recourse picture. CAR-T itself carries serious potential complications — cytokine release syndrome and neurotoxicity among them — that demand experienced ICU backup. And for an international patient there are practical fault lines: medical records that don't transfer cleanly, consent forms in another language, and the handover back to your home oncologist after you fly out.

None of these risks argue against considering China. They argue for independent verification — of the specific hospital, the specific product, the physician team's track record with your specific cancer — before money moves or flights are booked.

How to approach it: a practical sequence

Remote review first. Share your diagnosis, staging, and prior-treatment records for evaluation by the candidate centre before committing to travel.
Confirm the exact therapy and its status. Fully approved product, or investigator-initiated trial? The answer changes everything downstream.
Get a written, itemised cost estimate covering the therapy, hospitalisation, complication management, and follow-up imaging or labs.
Plan the timeline realistically. Eligibility work-up, cell collection, manufacturing, reinfusion, and post-infusion monitoring typically mean several weeks in-country.
Arrange the handover home. Your home oncologist should receive the full protocol and monitoring plan before you leave China, not after.

This is precisely the terrain where an independent coordinator earns its keep — not by selling you a hospital, but by verifying options, managing records and interpreters, and being on the ground with you. (Lengdeh is fee-only: any referral fee or commission a facility offers is rebated to the client in full, so our only incentive is that the coordination goes well.)

Frequently asked questions

How much does CAR-T therapy cost in China compared to the US?

Base treatment in China is widely reported at roughly US$30,000–$140,000 depending on the product and hospital, versus roughly US$275,000–$475,000 in the United States before hospital and supportive-care costs. All-in costs are typically several times lower in China. Always obtain a written quote for your specific case.

Why is CAR-T treatment faster in China?

Cells are engineered and manufactured locally, so the vein-to-vein timeline can shrink to days — cases of around eight days have been reported — versus the weeks or months common in Western systems. For fast-progressing blood cancers, that difference can determine whether a patient remains well enough to receive the therapy at all.

Is it safe for foreigners to get cancer treatment in China?

Leading academic hospitals in Beijing and Shanghai run some of the world's largest CAR-T programmes, and China's regulator had approved eight CAR-T products as of late 2025. But quality varies between institutions, some therapies are offered under trial frameworks, and language, consent, and follow-up care all require planning. Independent verification of the specific centre and protocol is essential.

How do I arrange treatment in China as an international patient?

Start with remote review of your medical records, confirm eligibility and a written cost estimate, arrange a medical visa, then plan for several weeks in-country covering work-up, cell collection, manufacturing, reinfusion, and monitoring — with a structured handover to your home oncologist afterwards.

What questions should I ask before choosing an overseas treatment centre?

Whether the therapy is fully approved or trial-stage; how many patients with your specific cancer the centre has treated, and outcomes; what the written all-in cost covers; how complications are managed and what ICU capability exists; what English-language support is available; and how follow-up will be coordinated at home.

Considering treatment or screening in Asia?

Lengdeh coordinates premium healthcare across Asia on a strictly fee-only basis — 100% of any referral fee is rebated back to you, so our advice stays independent.

Talk to us

Sources: BBC World Service, Asia Specific: "Why cancer patients are flying to China for treatment" · Yicai Global, Nov 2025 · Inside Precision Medicine, 2026

Medical disclaimer: This article is general information, not medical advice. Treatment decisions should always be made with your own oncologist and treating physicians. Costs, approvals, and availability change; figures above reflect published reporting as of August 2026. Lengdeh coordinates care and does not provide medical treatment or own any medical facility.